These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32397211)

  • 1. Live-Cell Cardiac-Specific High-Throughput Screening Platform for Drug-Like Molecules that Enhance Ca
    Schaaf TM; Kleinboehl E; Yuen SL; Roelike LN; Svensson B; Thompson AR; Cornea RL; Thomas DD
    Cells; 2020 May; 9(5):. PubMed ID: 32397211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting protein-protein interactions for therapeutic discovery via FRET-based high-throughput screening in living cells.
    Stroik DR; Yuen SL; Janicek KA; Schaaf TM; Li J; Ceholski DK; Hajjar RJ; Cornea RL; Thomas DD
    Sci Rep; 2018 Aug; 8(1):12560. PubMed ID: 30135432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The transmembrane peptide DWORF activates SERCA2a via dual mechanisms.
    Li A; Yuen SL; Stroik DR; Kleinboehl E; Cornea RL; Thomas DD
    J Biol Chem; 2021; 296():100412. PubMed ID: 33581112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Throughput Spectral and Lifetime-Based FRET Screening in Living Cells to Identify Small-Molecule Effectors of SERCA.
    Schaaf TM; Peterson KC; Grant BD; Bawaskar P; Yuen S; Li J; Muretta JM; Gillispie GD; Thomas DD
    SLAS Discov; 2017 Mar; 22(3):262-273. PubMed ID: 27899691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral expression of a SERCA2a-activating PLB mutant improves calcium cycling and synchronicity in dilated cardiomyopathic hiPSC-CMs.
    Stroik DR; Ceholski DK; Bidwell PA; Mleczko J; Thanel PF; Kamdar F; Autry JM; Cornea RL; Thomas DD
    J Mol Cell Cardiol; 2020 Jan; 138():59-65. PubMed ID: 31751570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SERCA2a-phospholamban interaction monitored by an interposed circularly permutated green fluorescent protein.
    Arnold ME; Dostmann WR; Martin J; Previs MJ; Palmer B; LeWinter M; Meyer M
    Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2188-H2200. PubMed ID: 33861144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of enzyme modulators via high-throughput time-resolved FRET in living cells.
    Gruber SJ; Cornea RL; Li J; Peterson KC; Schaaf TM; Gillispie GD; Dahl R; Zsebo KM; Robia SL; Thomas DD
    J Biomol Screen; 2014 Feb; 19(2):215-22. PubMed ID: 24436077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing phospholamban to sarco(endo)plasmic reticulum Ca2+-ATPase 2a (SERCA2a) protein binding interactions in human cardiac sarcoplasmic reticulum vesicles using chemical cross-linking.
    Akin BL; Jones LR
    J Biol Chem; 2012 Mar; 287(10):7582-93. PubMed ID: 22247554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phospholamban-tethered cardiac Ca2+ pump reveals stoichiometry and dynamic interactions between the two proteins.
    Chen Z
    Biochem J; 2011 Oct; 439(2):313-9. PubMed ID: 21728996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylation of phospholamban promotes SERCA2a activation by dwarf open reading frame (DWORF).
    Bovo E; Jamrozik T; Kahn D; Karkut P; Robia SL; Zima AV
    Cell Calcium; 2024 Jul; 121():102910. PubMed ID: 38823350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescence lifetime FRET assay for live-cell high-throughput screening of the cardiac SERCA pump yields multiple classes of small-molecule allosteric modulators.
    Roopnarine O; Yuen SL; Thompson AR; Roelike LN; Rebbeck RT; Bidwell PA; Aldrich CC; Cornea RL; Thomas DD
    Sci Rep; 2023 Jul; 13(1):10673. PubMed ID: 37393380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative affinity of calcium pump isoforms for phospholamban quantified by fluorescence resonance energy transfer.
    Hou Z; Robia SL
    J Mol Biol; 2010 Sep; 402(1):210-6. PubMed ID: 20643144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput FRET assay yields allosteric SERCA activators.
    Cornea RL; Gruber SJ; Lockamy EL; Muretta JM; Jin D; Chen J; Dahl R; Bartfai T; Zsebo KM; Gillispie GD; Thomas DD
    J Biomol Screen; 2013 Jan; 18(1):97-107. PubMed ID: 22923787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phospholamban inhibits the cardiac calcium pump by interrupting an allosteric activation pathway.
    Cleary SR; Seflova J; Cho EE; Bisht K; Khandelia H; Espinoza-Fonseca LM; Robia SL
    J Biol Chem; 2024 May; 300(5):107267. PubMed ID: 38583863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phospholamban C-terminal residues are critical determinants of the structure and function of the calcium ATPase regulatory complex.
    Abrol N; Smolin N; Armanious G; Ceholski DK; Trieber CA; Young HS; Robia SL
    J Biol Chem; 2014 Sep; 289(37):25855-66. PubMed ID: 25074938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectral Unmixing Plate Reader: High-Throughput, High-Precision FRET Assays in Living Cells.
    Schaaf TM; Peterson KC; Grant BD; Thomas DD; Gillispie GD
    SLAS Discov; 2017 Mar; 22(3):250-261. PubMed ID: 27879398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Competitive displacement of wild-type phospholamban from the Ca2+-free cardiac calcium pump by phospholamban mutants with different binding affinities.
    Chen Z
    J Mol Cell Cardiol; 2014 Nov; 76():130-7. PubMed ID: 25194792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association with SERCA2a directs phospholamban trafficking to sarcoplasmic reticulum from a nuclear envelope pool.
    He W; Huang D; Guo S; Wang D; Guo J; Cala SE; Chen Z
    J Mol Cell Cardiol; 2020 Jun; 143():107-119. PubMed ID: 32353354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phospholamban mutants compete with wild type for SERCA binding in living cells.
    Gruber SJ; Haydon S; Thomas DD
    Biochem Biophys Res Commun; 2012 Apr; 420(2):236-40. PubMed ID: 22405774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition.
    Ferrandi M; Barassi P; Tadini-Buoninsegni F; Bartolommei G; Molinari I; Tripodi MG; Reina C; Moncelli MR; Bianchi G; Ferrari P
    Br J Pharmacol; 2013 Aug; 169(8):1849-61. PubMed ID: 23763364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.